In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model
Fig 6
Drug cytotoxicity results for the clinical cases.
The estimated sum of cell kill rates, CKRsum for the cisplatin-based doublet regimen given to each clinical case (denoted by its ID number) is displayed. Latin Hypercube Sampling has been run to produce two sets of value combinations of model parameters, one for the Adenocarcinoma (ADC) and one for the Squamous Cell Carcinoma (SCC) clinical cases. For each value combination the CKRsum that results in the clinically observed volume reduction is determined. At any given case the dot denotes the median (50th percentile) of the N estimated values, the lower and upper boundaries of the solid line denote the 10th and 90th percentile, whereas the dashed line extends to the two extreme values of the estimated CKRsum.